EIF3A and lung carcinoma: To confirm that eIF3a is associated with cisplatin chemotherapy resistance in lung cancer, we tested eIF3a mRNA and protein expression in A549 (cisplatin sensitive cell line) and A549/DDP cells (cisplatin resistant cell line).